Porzycki P, et al. - In this preliminary study, researchers analyzed the correlation between clinicopathological data and circulating microRNA (miRNA) expression levels in the serum of patients with a diagnosis of prostate cancer (PCa) and healthy individuals (controls) to find effective biomarkers. A population of 20 patients with mean age of 68.6 years and mean prostate-specific antigen (PSA) of 21.3 ng/ml was included and levels of five miRNAs (miR-106b, miR-141, miR-21, mir-34a, and miR-375) were quantified by RT-qPCR. Based on the results, which lend support to previous findings, the detection of miRNA (miR-141-3p, miR-21, and miR-375) can possibly be a tool to distinguish prostate cancer patients from healthy controls.